Pharmaceutical News

RSS

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014

Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.

28 Jun 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

Ohm receives U.S. FDA approval to manufacture and market Valsartan

Ohm Laboratories, Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced today that Ohm has received approval from the U.S. Food and Drug Administration to manufacture and market Valsartan 40 mg, 80 mg, 160 mg, and 320 mg tablets on an exclusive basis.

27 Jun 2014

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

27 Jun 2014

HOC pleads guilty for selling misbranded, unapproved chemotherapy drugs

Hematology and Oncology Center (HOC) PLLC of Somerset, Kentucky has pleaded guilty to federal charges that the firm purchased and sold unapproved and improperly labeled chemotherapy drugs.

27 Jun 2014

Researchers develop new, cost-effective method for producing Janus capsules

Everything depends on how you look at them. Looking from one side you will see one face; and when looking from the opposite side - you will see a different one.

27 Jun 2014

Cancer drug shows promise in treating blood cell disorders

Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell's natural defenses and efficiently insert disease-fighting genes into the cell's genome.

27 Jun 2014

Research: TB infection among people taking corticosteroid pills may be underestimated

Tuberculosis infection among people taking corticosteroid pills may be underestimated, new research suggests.

26 Jun 2014

Use of low-dose aspirin associated with cutting risk of pancreatic cancer in half

The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

26 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological issues, experienced significant, sustained weight loss while taking oral medication daily over a number of years to manage symptoms of the disease.

25 Jun 2014

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.

24 Jun 2014

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it.

24 Jun 2014

Gelesis100 capsule leads to greater weight loss in overweight, obese individuals

A new "smart pill" called Gelesis100 safely leads to greater weight loss in overweight and obese individuals compared with those who receive an active comparator/placebo capsule, while all subjects have similar diet and exercise instructions, an international multicenter study finds.

24 Jun 2014

New invention provides simple, highly effective way for patients to self-treat keloid scars

Scars - in particular keloid scars that result from overgrowth of skin tissue after injuries or surgeries - are unsightly and can even lead to disfigurement and psychological problems of affected patients. Individuals with darker pigmentation - in particular people with African, Hispanic or South-Asian genetic background - are more likely to develop this skin tissue disorder.

24 Jun 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

23 Jun 2014

Treatment with diabetes drug liraglutide improves cardiovascular risk factors

Treatment with the diabetes drug liraglutide, in combination with diet and exercise, led to a significant reduction in weight and improved a number of cardiovascular risk factors, including high blood pressure and high cholesterol, according to a multicenter study.

23 Jun 2014

Pharmaceutical News

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Ohm receives U.S. FDA approval to manufacture and market Valsartan

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

HOC pleads guilty for selling misbranded, unapproved chemotherapy drugs

Researchers develop new, cost-effective method for producing Janus capsules

Cancer drug shows promise in treating blood cell disorders

Research: TB infection among people taking corticosteroid pills may be underestimated

Use of low-dose aspirin associated with cutting risk of pancreatic cancer in half

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

SLU researchers discover pain pathway and potential way to block it

Gelesis100 capsule leads to greater weight loss in overweight, obese individuals

New invention provides simple, highly effective way for patients to self-treat keloid scars

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Treatment with diabetes drug liraglutide improves cardiovascular risk factors

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News